GSA Capital Partners LLP Acquires New Position in Anika Therapeutics Inc. $ANIK

GSA Capital Partners LLP acquired a new stake in Anika Therapeutics Inc. (NASDAQ:ANIK) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 26,183 shares of the biotechnology company’s stock, valued at approximately $383,000. GSA Capital Partners LLP owned 0.20% of Anika Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ANIK. Quarry LP purchased a new position in shares of Anika Therapeutics during the 3rd quarter valued at $71,000. CWM LLC raised its holdings in shares of Anika Therapeutics by 14.5% during the fourth quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 1,080 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Anika Therapeutics during the third quarter valued at $95,000. Ieq Capital LLC acquired a new stake in Anika Therapeutics during the fourth quarter valued at $97,000. Finally, Inscription Capital LLC purchased a new position in Anika Therapeutics in the fourth quarter valued at about $122,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Stock Performance

ANIK opened at $21.78 on Friday. The company has a market cap of $291.42 million, a PE ratio of -80.66, a price-to-earnings-growth ratio of 15.56 and a beta of 0.20. The stock has a 50-day moving average of $17.05 and a 200-day moving average of $14.98. Anika Therapeutics Inc. has a 52-week low of $8.37 and a 52-week high of $22.88.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.39. The business had revenue of $32.61 million for the quarter, compared to the consensus estimate of $29.21 million. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%. On average, research analysts predict that Anika Therapeutics Inc. will post 0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ANIK shares. B. Riley Financial upped their target price on Anika Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Zacks Research raised Anika Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Anika Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Anika Therapeutics Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.